BRCA1 Immunohistochemistry in a Molecularly Characterized Cohort of Ovarian High-Grade Serous Carcinomas

No abstract is available for this paper.

• Publication year

  2013

• Venue

  American Journal of Surgical Pathology

• Publication date

  2013-01-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1097/PAS.0b013e31826cabbdPMID 23232854PMCID PMC3531916
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Testing Women With Endometrial Cancer to Detect Lynch Syndrome

  2012cited by this paper
• Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma

  2012cited by this paper
• Testing women with endometrial cancer to detect Lynch syndrome.

  2011cited by this paper
• Integrated Genomic Analyses of Ovarian Carcinoma

  2011cited by this paper
• Breast cancer 1 (BRCA1) protein expression as a prognostic marker in sporadic epithelial ovarian carcinoma: an NCIC CTG OV.16 correlative study.

  2011cited by this paper
• Identification of BRCA1‐deficient ovarian cancers

  2011cited by this paper
• Loss of BRCA1 Protein Expression as Indicator of the BRCAness Phenotype Is Associated With Favorable Overall Survival After Complete Resection of Sporadic Ovarian Cancer

  2011cited by this paper
• Assays for hypermethylation of the BRCA1 gene promoter in tumor cells to predict sensitivity to PARP-inhibitor therapy.

  2011cited by this paper
• Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations

  2011cited by this paper
• Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2.

  2011cited by this paper
• BRCA1 is both a prognostic and predictive biomarker of response to chemotherapy in sporadic epithelial ovarian cancer.

  2011cited by this paper
• Lynch Syndrome Screening Strategies Among Newly Diagnosed Endometrial Cancer Patients

  2010cited by this paper
• Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer.

  2010cited by this paper
• Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer.

  2010cited by this paper
• Selection of Endometrial Carcinomas for DNA Mismatch Repair Protein Immunohistochemistry Using Patient Age and Tumor Morphology Enhances Detection of Mismatch Repair Abnormalities

  2009cited by this paper
• Lynch Syndrome Screening Strategies Among Newly Diagnosed Endometrial Cancer Patients

  2009cited by this paper
• Heterogenic Loss of the Wild-Type BRCA Allele in Human Breast Tumorigenesis

  2007cited by this paper
• Familial Breast/Ovarian Cancer and BRCA1/2 Genetic Screening: The Role of Immunohistochemistry as an Additional Method in the Selection of Patients

  2007cited by this paper
• Utility of Immunohistochemistry in Predicting Microsatellite Instability in Endometrial Carcinoma

  2007cited by this paper
• Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability.

  2004cited by this paper
• Improved survival in women with BRCA‐associated ovarian carcinoma

  2003cited by this paper
• Screening of BRCA1 Mutation Using Immunohistochemical Staining with C‐Terminal and N‐Terminal Antibodies in Familial Ovarian Cancers

  2000cited by this paper
• An antibody assay predictive of BRCA1 mutations in ovarian tumors and normal tissue.

  2000cited by this paper
• Cancer of the ovary.

  1994cited by this paper
• Cancer of the ovary.

  1993cited by this paper

• Unraveling SET: Exploring ovarian high-grade serous carcinoma and its BRCA1/2 immunoexpression.

  2025cites this paper
• BRCA1 Protein Expression in Epithelial Ovarian Cancer and Associated Clinicopathological Factors in Uganda

  2024cites this paper
• Type I or Type II Endometrial Carcinoma? Role of BRCA1 Immunohistochemistry

  2024cites this paper
• BRCA1 expression, its correlation with clinicopathological features and response to neoadjuvant chemotherapy in high grade serous ovarian cancer from an Indian centre

  2023cites this paper
• HSF-1/miR-145-5p transcriptional axis enhances hyperthermic intraperitoneal chemotherapy efficacy on peritoneal ovarian carcinosis

  2023cites this paper
• Low PARP-1 expression level is an indicator of poor prognosis in patients with stage II and III gastric cancer

  2022cites this paper
• Combined BRCA2 and MAGEC3 Expression Predict Outcome in Advanced Ovarian Cancers

  2022cites this paper
• Prognostic Relevance of BRCA1 Expression in Survival of Patients With Cervical Cancer

  2021cites this paper
• Hereditary Breast and Ovarian Cancer: Current Concepts of Prevention and Treatment

  2021cites this paper
• Potential role of BRCA1 protein expression as a prognostic tissue biomarker in breast carcinoma: An immunohistochemical and clinicopathologic study from South India

  2021cites this paper
• Analysis of matched primary and recurrent BRCA1/2 mutation-associated tumors identifies recurrence-specific drivers

  2021cites this paper
• Loss of BRCA1 expression and morphological features associated with BRCA1 promoter methylation status in triple-negative breast cancer

  2021cites this paper
• BRCA1 Promoter Hypermethylation is Associated with Good Prognosis and Chemosensitivity in Triple-Negative Breast Cancer

  2020influential citation
• HRness in Breast and Ovarian Cancers

  2020cites this paper
• BRCA immunohistochemistry for screening of BRCA mutation in epithelial ovarian cancer patients

  2020influential citation
• Pathology of Hereditary Breast and Ovarian Cancer

  2020cites this paper
• Implementation of Hereditary Gynecologic Cancer Clinic Utilizing Existing All Screening and Genetic Methods in Community-Based Hospital by Surgeon

  2020cites this paper
• Clonal Evolution of TP53 c.375+1G>A Mutation in Pre- and Post- Neo-Adjuvant Chemotherapy (NACT) Tumor Samples in High-Grade Serous Ovarian Cancer (HGSOC)

  2019cites this paper
• The clinical importance of BRCAness in a population-based cohort of Danish epithelial ovarian cancer

  2019cites this paper
• Epithelial Tumors of the Ovary

  2019cites this paper
• Clinical significance of BRCA1 and BRCA2 mRNA and protein expression in patients with sporadic gastric cancer

  2019cites this paper
• Immunohistochemistry for the detection of BRCA1 and BRCA2 proteins in patients with ovarian cancer: a systematic review

  2019cites this paper
• Epithelial Ovarian Cancer Prevention

  2019cites this paper
• BRCA1, Ki67, and β-Catenin Immunoexpression Is Not Related to Differentiation, Platinum Response, or Prognosis in Women With Low- and High-Grade Serous Ovarian Carcinoma.

  2018influential citation
• Hereditary breast cancer; Genetic penetrance and current status with BRCA

  2018cites this paper
• Rôle de la neurotensine dans la progression des adénocarcinomes de l’endomètre et de l’ovaire

  2018influential citation
• BRCA1 and BRCA2 expression patterns and prognostic significance in digestive system cancers.

  2018cites this paper
• BRCA1, Ki67, and β-Catenin Immunoexpression Is Not Related to Differentiation, Platinum Response, or Prognosis in Women With Low- and High-Grade Serous Ovarian Carcinoma

  2018influential citation
• BRCA1/2 Mutations in Salivary Pleomorphic Adenoma and Carcinoma-ex-Pleomorphic Adenoma

  2017cites this paper
• Synchronous Bilateral Tubal Serous Carcinomas in a Patient With Exon 13 Duplication and Loss of Function of BRCA1

  2017cites this paper
• Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer

  2017cites this paper
• [Hereditary breast and ovarian cancer].

  2017cites this paper
• Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition.

  2017cites this paper
• Gynaecological neoplasms in common familial syndromes (Lynch and HBOC).

  2017cites this paper
• BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers

  2017cites this paper
• Role of Biomarkers in the Development of PARP Inhibitors

  2016cites this paper
• The Prognostic Value of BRCA1 and PARP Expression in Epithelial Ovarian Carcinoma: Immunohistochemical Detection

  2016influential citation
• Assessment of PARP protein expression in epithelial ovarian cancer by ELISA pharmacodynamic assay and immunohistochemistry

  2016cites this paper
• Individual and Combined Expression of DNA Damage Response Molecules PARP1, γH2AX, BRCA1, and BRCA2 Predict Shorter Survival of Soft Tissue Sarcoma Patients

  2016cites this paper
• Overexpression of BRCA1 or BRCA2 in prostatectomy specimens is predictive of biochemical recurrence after radical prostatectomy

  2016cites this paper
• Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations.

  2016cites this paper
• Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer

  2016cites this paper
• Evaluation of the methods to identify patients who may benefit from PARP inhibitor use.

  2016cites this paper
• Expression of DNA Damage Response Molecules PARP1, γH2AX, BRCA1, and BRCA2 Predicts Poor Survival of Breast Carcinoma Patients 1 See-HyoungPark*, SangJaeNoh † ,KyoungMinKim † ,

  2015cites this paper
• Zane Simtniece PROGNOSTIC FACTORS OF SURGICALLY TREATED PANCREATIC CANCER Summary of the Doctoral Thesis for obtaining the degree of a Doctor of Medicine Speciality – Pathology

  2015cites this paper
• Sox2 Gene Amplification Significantly Impacts Overall Survival in Serous Epithelial Ovarian Cancer

  2015cites this paper
• PARP inhibitors: the journey from research hypothesis to clinical approval.

  2015cites this paper
• The expression of DBC1/CCAR2 is associated with poor prognosis of ovarian carcinoma

  2015cites this paper
• Expression of DNA Damage Response Molecules PARP1, γH2AX, BRCA1, and BRCA2 Predicts Poor Survival of Breast Carcinoma Patients1

  2015cites this paper
• Risk prediction model for epithelial ovarian cancer using molecular markers and clinical characteristics

  2015cites this paper
• 33. Current Status and Future Direction of PARP Inhibition in Cancer Therapy

  2015cites this paper
• Hereditary Risk Evaluation for Borderline Ovarian Tumors Based on Immunohistochemistry

  2014cites this paper
• Molecular steps towards improving prognosis in ovarian cancer

  2014cites this paper
• Tumors of the breast and female genital organs

  2014cites this paper
• Immunohistochemical Loss of BRCA1 Protein in Uterine Serous Carcinoma

  2014cites this paper
• Invasion patterns of metastatic high-grade serous carcinoma of ovary or fallopian tube associated with BRCA deficiency

  2014cites this paper
• The performance of BRCA1 immunohistochemistry for detecting germline, somatic, and epigenetic BRCA1 loss in high-grade serous ovarian cancer.

  2014cites this paper
• Epigenetic, Genetic and Environmental Interactions in Esophageal Squamous Cell Carcinoma from Northeast India

  2013cites this paper